Wegovy
PulseAugur coverage of Wegovy — every cluster mentioning Wegovy across labs, papers, and developer communities, ranked by signal.
- developed by Novo Nordisk 90%
- parent of Novo Nordisk 90%
- subsidiary of Novo Nordisk 90%
- competes with Ozempic 80%
- instance of Ozempic 70%
- affiliated with Ozempic 70%
- used by Novo Nordisk 70%
- competes with tirzepatide 70%
- affiliated with Novo Nordisk 70%
- used by Centers for Medicare and Medicaid Services 60%
- competes with Novo Nordisk 50%
4 day(s) with sentiment data
-
Waters Corp. launches AI tool to accelerate pharmaceutical quality testing
Waters Corp. has launched a new AI-powered tool called Peak Integration, designed to streamline quality testing in pharmaceutical drug discovery and manufacturing. This integration within their Empower software platform…
-
LLM agent AskGLP1 maps GLP-1 patient experiences to knowledge graph
Researchers have developed AskGLP1, an LLM-powered agent designed to extract and structure information about GLP-1 medication experiences from online patient narratives. The system processes millions of posts from platf…
-
GLP-1 Medications Reshape Travel Industry: Hotels, Menus, and Wellness Adapt
The rise of GLP-1 medications like Ozempic and Wegovy is influencing the travel industry, prompting changes in hotel services and offerings. Travelers using these drugs are seeking specific amenities such as in-room med…
-
GLP-1 drugs poised to outpace AI in impact and revenue
GLP-1 drugs are projected to have a more significant impact than artificial intelligence over the next two years, with sales expected to surpass generative AI revenue by the end of 2025. While initial costs were high, p…
-
GLP-1 drugs drive US obesity rate decline amid patent competition
The obesity rate in the United States has begun to decline, largely attributed to the increasing availability and affordability of GLP-1 weight-loss medications like Wegovy. These drugs, initially developed from a pepti…
-
Ozempic, Wegovy linked to lower Alzheimer's risk in new study
A new study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association suggests a link between semaglutide, the active ingredient in Ozempic and Wegovy, and a reduced risk of Alzheimer's disease. Re…
-
Weight-loss drugs may slow biological aging, studies suggest
Weight-loss drugs like GLP-1s from Eli Lilly and Novo Nordisk are showing potential to slow biological aging, according to molecular aging clocks. These drugs, which stimulate appetite suppression, have demonstrated a r…
-
Ozempic-maker Novo Nordisk rebrands to 'Novo' amid competition
Novo Nordisk, the pharmaceutical company known for its weight-loss drugs Ozempic and Wegovy, is rebranding to simply 'Novo'. This change aims to make the brand more memorable and relevant for consumers as the company fa…
-
IHH Healthcare CEO launches longevity program amid Asia's aging population
IHH Healthcare, led by CEO Prem Kumar Nair, is launching a new preventive health and longevity program called "Healthspan" to address the growing issue of lifestyle diseases in Asia's aging population. The initiative, c…
-
Medicare GLP-1 discount program excludes patients with certain medical conditions
A new Medicare pilot program offering GLP-1 medications for weight loss at a reduced cost of $50 per month has encountered issues with patient eligibility. While intended to help those struggling with the high price of …
-
GLP-1 drugs transform obesity treatment but affordability crisis looms
GLP-1 drugs like Ozempic, Wegovy, and Zepbound are revolutionizing obesity treatment by shifting focus from late-stage interventions to proactive weight management. These medications have shown significant reductions in…
-
Eli Lilly escalates fight against black market retatrutide
Eli Lilly & Co. is intensifying its efforts to combat the illicit market for retatrutide, an experimental weight-loss drug. The company has filed lawsuits against businesses in the US, particularly in Texas, that are il…
-
GLP-1 Drugs Boost Women's Employment More Than College Degrees, Study Finds
A study from Harvard University, published by the National Bureau of Economic Research, suggests that GLP-1 drugs, such as Ozempic and Wegovy, have a greater impact on increasing women's employment rates than obtaining …
-
Bank of America spends $250M annually on weight loss drugs for staff
Bank of America is significantly investing in employee wellness by spending over $250 million annually on weight loss drugs like Ozempic and Wegovy. CEO Brian Moynihan views this as a crucial investment in employee heal…
-
Companies tap retired CEOs amid succession planning crisis
Companies are increasingly turning to retired CEOs to fill leadership gaps as internal succession pipelines become depleted. This trend is driven by executives staying in their roles longer, leading to potential success…
-
Novo Nordisk faces growth challenges after Wegovy success, rival Eli Lilly gains ground
Novo Nordisk, once Europe's most valuable company due to the success of its weight-loss drugs Ozempic and Wegovy, is facing challenges in developing new blockbuster treatments. Its rival, Eli Lilly and Company, has gain…
-
GLP-1 drugs like Ozempic may cause unlisted side effects, study finds
New research indicates that GLP-1 medications like Ozempic and Wegovy may have side effects not listed on their labels. A study analyzing Reddit posts found that nearly half of semaglutide and tirzepatide users reported…
-
Medicare launches GLP-1 bridge program for weight loss drugs
The Medicare Bridge program, initiated by the Trump administration, offers eligible seniors and disabled individuals access to certain GLP-1 weight loss medications for a flat $50 monthly co-payment. This demonstration …
-
FDA peptide vote could unlock new telehealth market, mirroring Ozempic boom
The FDA's upcoming vote on seven peptides, including BPC-157 and TB-500, could legitimize a new multibillion-dollar market for wellness injectables. Telehealth companies like Hims & Hers, which previously profited from …
-
Medicare launches $50/month GLP-1 weight loss drug program
The Trump administration has launched a temporary Medicare Bridge program to provide some beneficiaries with access to popular weight loss medications like tirzepatide and semaglutide for a flat $50 monthly co-payment. …